dievini Hopp BioTech holding GmbH & Co. KG
  • Home
  • Management
  • Portfolio
  • Unternehmensmeldungen
  • Impressum
  • Datenschutz
  • English
dievini Hopp BioTech holding GmbH & Co. KG
  • Home
  • Management
  • Portfolio
  • Unternehmensmeldungen
  • Impressum
  • Datenschutz
  • English

08.11.2021: AC Immune SA

AC Immune Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Announced the first positive cognitive results for a Tau-targeting monoclonal antibody in mild-to-moderate Alzheimer’s disease

Closed its strategic acquisition of an industry-leading Parkinson’s disease vaccine and an equity financing led by key investors

Appointed Monica Shaw, M.D., and Prof. Monika Bütler, Dr. Oec., to the Board of Directors

Strong financial position of CHF 188.6 million1 ensures the Company is fully financed through at least Q1 2024

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported its financial results for the quarter ended September 30, 2021 and provided a corporate update.

Den gesamten Artikel lesen Sie bitte hier


AC Immune SA, News 2021
04.11.2021: AC Immune SA
09.11.2021: Immatics Biotechnologies GmbH

dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz